Pro-Dex (PDEX) Stock Price, News & Analysis

Company Overview

Pro-Dex, Inc. is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems. Pro-Dex combines in-house design, precision machining and assembly to support complex applications, ensuring tight tolerances and compliance with industry standards.

Headquartered in Irvine, California, Pro-Dex operates manufacturing and research facilities in the United States and maintains a global distribution network that spans North America, Europe and Asia. This geographic reach enables the company to provide technical support and aftermarket services to its customers worldwide.

Founded in 1975, Pro-Dex has built its reputation on engineering expertise, quality management and regulatory compliance. The company’s leadership team brings extensive experience in precision device manufacturing, product development and quality systems, guiding Pro-Dex through continuous expansion of its capabilities and market presence.

Key Stats

• Today's Range: $34.51 to $35.02
• 50-Day Range: $32.62 to $50.05
• 52-Week Range: $26.28 to $70.26
• Volume: 786 shs
• Average Volume: 44,499 shs
• Market Capitalization: $111.93 million
• P/E Ratio: 12.72
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Moderate Buy

Pro-Dex Stock Analysis - MarketRank™

Pro-Dex scored higher than 62% of companies evaluated by MarketBeat, and ranked 419th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pro-Dex has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Pro-Dex has a consensus price target of $56.00, representing about 61.2% upside from its current price of $34.74.

Amount of Analyst Coverage

Pro-Dex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3.00%

Earnings Growth

Earnings for Pro-Dex are expected to grow by 3.00% in the coming year, from $2.00 to $2.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pro-Dex is 12.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.35.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pro-Dex is 12.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.48.

Price to Book Value per Share Ratio

Pro-Dex has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.42% of the float of Pro-Dex has been sold short.

Short Interest Ratio / Days to Cover

Pro-Dex has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Pro-Dex has recently decreased by 0.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pro-Dex does not currently pay a dividend.

Dividend Growth

Pro-Dex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.42% of the float of Pro-Dex has been sold short.

Short Interest Ratio / Days to Cover

Pro-Dex has a short interest ratio ("days to cover") of 5.

Change versus previous month

Short interest in Pro-Dex has recently decreased by 0.19%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.67

News Sentiment

Pro-Dex has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Pro-Dex this week, compared to 1 article on an average week.

Search Interest

10 people have searched for PDEX on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.

MarketBeat Follows

6 people have added Pro-Dex to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pro-Dex insiders have not sold or bought any company stock.

Percentage Held by Insiders

47.50% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 15.28% of the stock of Pro-Dex is held by institutions.

PDEX Stock Analysis - Frequently Asked Questions

How have PDEX shares performed this year?

Pro-Dex's stock was trading at $46.75 on January 1st, 2025. Since then, PDEX stock has decreased by 25.7% and is now trading at $34.74.

How were Pro-Dex's earnings last quarter?

Pro-Dex, Inc. (NASDAQ:PDEX) posted its quarterly earnings results on Thursday, September, 4th. The medical instruments supplier reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.47 by $0.11. The medical instruments supplier had revenue of $17.49 million for the quarter, compared to analyst estimates of $17.90 million. Pro-Dex had a net margin of 13.48% and a trailing twelve-month return on equity of 26.67%.

How do I buy shares of Pro-Dex?

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pro-Dex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL).

Company Calendar

• Last Earnings: 9/04/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED/DENTAL - SUPP
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PDEX
• CIK: 788920
• Web: www.pro-dex.com
• Phone: (949) 769-3200
• Fax: 949-769-3281
• Employees: 140
• Year Founded: 1975

Price Target and Rating

• Average Price Target for Pro-Dex: $56.00
• High Price Target: $56.00
• Low Price Target: $56.00
• Potential Upside/Downside: +61.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.70
• Trailing P/E Ratio: 12.87
• Forward P/E Ratio: 17.37
• P/E Growth: N/A
• Net Income: $8.98 million
• Net Margins: 13.48%
• Pretax Margin: 18.11%
• Return on Equity: 26.67%
• Return on Assets: 14.95%

Debt

• Debt-to-Equity Ratio: 0.25
• Current Ratio: 3.23
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $66.59 million
• Price / Sales: 1.70
• Cash Flow: $3.32 per share
• Price / Cash Flow: 10.47
• Book Value: $11.23 per share
• Price / Book: 3.09

Miscellaneous

• Outstanding Shares: 3,260,000
• Free Float: 1,713,000
• Market Cap: $113.25 million
• Optionable: Not Optionable
• Beta: -0.11